Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Goldcrest Capital
Deal Size : $10.0 million
Deal Type : Financing
Junevity Raises $10M to Develop Cell Reset Therapeutics for Longevity
Details : The seed funding will enhance the RESET platform and develop company's first therapeutic candidates in Type 2 diabetes, obesity and frailty.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
February 13, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Goldcrest Capital
Deal Size : $10.0 million
Deal Type : Financing